影像引导容积旋转调强放疗联合同白蛋白结合型紫杉醇加顺铂治疗局部晚期宫颈癌:单臂剂量递增试验
该单臂1期试验采用标准3+3剂量递增设计,纳入22例组织学证实的IB2-IVA期局部晚期宫颈癌患者,评估影像引导容积旋转调强放疗联合同白蛋白结合型紫杉醇加顺铂的最大耐受剂量与剂量限制性毒性。估计最大耐受剂量为50 mg/m2,4例(18.0%)发生剂量限制性毒性,完全缓解率为90.9%。
要点
- 白蛋白结合型紫杉醇联合顺铂同步影像引导容积旋转调强放疗的最大耐受剂量为50 mg/m2。
- 4例(18.0%)发生剂量限制性毒性,包括低钾血症、深静脉血栓和会阴水肿。
- 完全缓解率为90.9%(20例)。
核心结论
- 在局部晚期宫颈癌患者中,影像引导容积旋转调强放疗联合同白蛋白结合型紫杉醇加顺铂时,白蛋白结合型紫杉醇的最大耐受剂量为50 mg/m2。
- 完全缓解率为90.9%。
研究设计与样本
- 单臂1期试验,采用标准3+3剂量递增设计,纳入组织学证实的IB2-IVA期局部晚期宫颈癌患者。
- 2019年9月至2021年8月共入组22例患者。
- 影像引导容积旋转调强放疗:盆腔50.4 Gy/28次,受累盆腔及腹主动脉旁淋巴结同步推量59.4 Gy/28次,后续高剂量率腔内近距离放疗总剂量30.0 Gy/5次、每周两次。
- 同步化疗:每周顺铂40 mg/m2,每周白蛋白结合型紫杉醇剂量递增(10、20、33、50、70 mg/m2/周)。
- 计划治疗时长8周;剂量限制性毒性定义为4级血液学毒性或3级及以上非血液学毒性;最大耐受剂量定义为剂量限制性毒性发生率≤33%的最高剂量。
主要发现
- 最常见不良事件为1-3级白细胞减少、腹泻和恶心/呕吐。
- 4例(18.0%)发生剂量限制性毒性:33 mg/m2组3级低钾血症1例(6例中1例),50 mg/m2组3级深静脉血栓1例(6例中1例),70 mg/m2组3级深静脉血栓1例(4例中1例)和3级会阴水肿1例(3例中1例)。
- 估计最大耐受剂量为50 mg/m2。
- 完全缓解20例(90.9%)。
关键数值与推荐
- 最大耐受剂量定义为剂量限制性毒性发生率≤33%的最高剂量。
- 剂量限制性毒性定义为4级血液学毒性或3级及以上非血液学毒性。
- 白蛋白结合型紫杉醇剂量递增水平为10、20、33、50、70 mg/m2/周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nanoparticle albumin-bound (nab) paclitaxel has improved uptake by tumor cells in comparison to paclitaxel. The aim of this study was to determine the maximal tolerated dose (MTD) and the dose-limiting toxicity (DLT) of nab-paclitaxel plus cisplatin with concurrent image guidance volume modulated arc therapy for locally advanced cervical cancer (LACC). METHODS AND MATERIALS: This single-arm phase 1 trial followed the standard 3 + 3 dose escalation design. Patients with histologically proven stage IB2-IVA LACC were eligible. Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0 Gy in 5 fractions, twice a week. Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m2) and weekly nab-paclitaxel at escalating doses (10, 20, 33, 50, and 70 mg/m2 per week). Duration of the planned treatment was 8 weeks. Grade 4 hematologic toxicity and grade 3 or above nonhematologic toxicity were considered as DLT. MTD was defined as the highest dose with ≤33% DLT. RESULTS: A total of 22 patients were enrolled from September 2019 to August 2021. The most common adverse events were grade 1 to 3 leukopenia, diarrhea, and nausea/vomiting. A total of 4 patients (18.0%) experienced DLT: grade 3 hypokalemia at 33 mg/m2 (1 of 6 subjects), grade 3 deep vein thrombosis at 50 mg/m2 (1 of 6) and 70 mg/m2 (1 of 4), and grade 3 perineum edema at 70 mg/m2 (1 of 3). The estimated MTD was 50 mg/m2. Complete response was observed in 20 patients (90.9%). CONCLUSIONS: In patients undergoing concurrent IG-VAMT with nab-paclitaxel plus cisplatin for LACC, MTD of nab-paclitaxel was 50 mg/m2. Complete response rate was 90.9%.
引用
- Jiang P, Deng X, Qu A, et al. Image Guidance Volume-Modulated Arc Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin for Patients With Locally Advanced Cervical Cancer: A Single-Arm Dose Escalation Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36402358. doi:10.1016/j.ijrobp.2022.11.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。